The presence of interferon affects the progression of non-alcoholic fatty liver disease

被引:3
|
作者
Mohlenberg, Michelle [1 ,2 ]
Eriksen, Peter Lykke [3 ]
Laursen, Tea Lund [3 ]
Nielsen, Mette Bak [4 ]
Dutoit, Stephen Jacques Hamilton [4 ]
Gronbaek, Henning [3 ]
Hartmann, Rune [1 ]
Thomsen, Karen Louise [3 ]
机构
[1] Aarhus Univ, Dept Mol Biol & Genet, Aarhus C, Denmark
[2] Aarhus Univ, Dept Biomed, Aarhus C, Denmark
[3] Aarhus Univ Hosp, Dept Hepatol & Gastroenterol, Aarhus N, Denmark
[4] Aarhus Univ Hosp, Dept Pathol, Aarhus N, Denmark
关键词
ALPHA; FIBROSIS; IL28B; POLYMORPHISMS; INFLAMMATION; STEATOHEPATITIS; ASSOCIATION; CLEARANCE; VARIANT; DAMAGE;
D O I
10.1038/s41435-022-00176-6
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Inflammation and metabolic dysfunction are hallmarks of the progression of non-alcoholic fatty liver disease (NAFLD), which is the fastest-growing liver disease worldwide. Emerging evidence indicates that innate immune mechanisms are essential drivers of fibrosis development in chronic inflammatory liver diseases, including NAFLD. In this study, 142 NAFLD patients were genotyped for three IFNL4 single-nucleotide variants in order to investigate the genetic relationship between IFNL4 and fibrosis in NAFLD patients. We observed an overrepresentation of the non-functional IFNL4 allele in patients with significant fibrosis (>F2). Next, we investigated the potential protective role of interferon (IFN) in relation to the development of liver fibrosis in an animal model of non-alcoholic steatohepatitis (NASH). In contradiction to our hypothesis, the results showed an increase in fibrosis in IFN treated animals. Our study clearly indicates that IFN is able to affect the development of liver fibrosis, although our clinical and experimental data are conflicting.
引用
收藏
页码:157 / 165
页数:9
相关论文
共 50 条
  • [21] Non-alcoholic fatty liver disease
    Bjornsson, Einar
    Angulo, Paul
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2007, 42 (09) : 1023 - 1030
  • [22] Non-alcoholic fatty liver disease
    Cua, IHY
    George, J
    HOSPITAL MEDICINE, 2005, 66 (02): : 106 - 111
  • [23] Non-alcoholic fatty liver disease
    Tuyama, Ana C.
    Chang, Charissa Y.
    JOURNAL OF DIABETES, 2012, 4 (03) : 266 - 280
  • [24] Non-alcoholic fatty Liver disease
    Calderaro, Julien
    Zafrani, Elie Serge
    ANNALES DE PATHOLOGIE, 2010, 30 (06) : 413 - 420
  • [25] Non-alcoholic fatty liver disease
    Farrell, Geoffrey C.
    Wardell, Rebecca
    Teoh, Narci
    Chitturi, Shiv
    INTERNAL MEDICINE JOURNAL, 2019, 49 (05) : 681 - 683
  • [26] Non-alcoholic fatty liver disease
    Adams, LA
    Angulo, P
    LIVER DISEASES: ADVANCES IN TREATMENT AND PREVENTION: IN HONOUR OF HANS POPPER'S 100TH BIRTHDAY, 2004, 137 : 250 - 270
  • [27] Non-Alcoholic Fatty Liver Disease
    Engin, Atilla
    OBESITY AND LIPOTOXICITY, 2017, 960 : 443 - 467
  • [28] Non-alcoholic fatty liver disease
    Brent A. Neuschwander-Tetri
    BMC Medicine, 15
  • [29] Non-alcoholic fatty liver disease
    Alba, LM
    Lindor, K
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2003, 17 (08) : 977 - 986
  • [30] Non-alcoholic fatty liver disease
    Sattar, Naveed
    Forrest, Ewan
    Preiss, David
    BMJ-BRITISH MEDICAL JOURNAL, 2014, 349